NA
LKFT

NewEdge Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

NewEdge Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$180 Hold
6
– – ﹤0.01% 4069
2025
Q4 		$196 Hold
6
– – ﹤0.01% 4133
2025
Q3 		$208 Hold
6
– – ﹤0.01% 4005
2025
Q2 		$168 Hold
6
– – ﹤0.01% 3884
2025
Q1 		$151 Hold
6
– – ﹤0.01% 3818
2024
Q4 		$165 Hold
6
– – ﹤0.01% 3754
2024
Q3 		$173 Sell
6
-8
-57% -$218 ﹤0.01% 3692
2024
Q2 		$347 Buy
14
+8
+133% +$227 ﹤0.01% 3613
2024
Q1 		$193 Hold
6
– – ﹤0.01% 3676
2023
Q4 		$244 Hold
6
– – ﹤0.01% 3590
2023
Q3 		$207 Hold
6
– – ﹤0.01% 3323
2023
Q2 		$244 Hold
6
– – ﹤0.01% 3370
2023
Q1 		$232 Hold
6
– – ﹤0.01% 3302
2022
Q4 		$0 Buy
+6
New +$252 ﹤0.01% 4124

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NewEdge Advisors's LKFT Position: Q1 2026 in Review

NewEdge Advisors held its Lakefront Biotherapeutics American Depositary Shares (LKFT) position steady in Q1 2026 at 6 shares worth $180. The position accounts for ﹤0.01% of the portfolio, ranked #4069.

NewEdge Advisors first reported a position in LKFT in Q4 2022 and has held it in 14 quarters since. The position peaked at $347 in Q2 2024. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • NewEdge Advisors held 6 shares of Lakefront Biotherapeutics American Depositary Shares worth $180 as of Q1 2026.
  • NewEdge Advisors left its Lakefront Biotherapeutics American Depositary Shares share count unchanged in Q1 2026.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #4069 holding.
  • NewEdge Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2022 and has held it in 14 quarters since.
  • NewEdge Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $347 in Q2 2024.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.